ADC Therapeutics Management
Management criteria checks 2/4
ADC Therapeutics' CEO is Ameet Mallik, appointed in May 2022, has a tenure of 1.92 years. total yearly compensation is $3.78M, comprised of 19.1% salary and 80.9% bonuses, including company stock and options. directly owns 0.84% of the company’s shares, worth $3.09M. The average tenure of the management team and the board of directors is 1.7 years and 3.4 years respectively.
Key information
Ameet Mallik
Chief executive officer
US$3.8m
Total compensation
| CEO salary percentage | 19.1% |
| CEO tenure | 1.9yrs |
| CEO ownership | 0.8% |
| Management average tenure | 1.7yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)
Mar 19ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues
Mar 17
ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth
Jan 18ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial
Dec 29An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued
Dec 14ADC Therapeutics: Navigating A Swirling Drain
Dec 01ADC Therapeutics: Slowly Moving Toward Solvency
Aug 29Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?
Jul 11ADC Therapeutics: Maybe A 2024 Story
May 29Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%
May 11ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business
Apr 18ADC Therapeutics stock slips after pricing stock offering by seller
Feb 02Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?
Jan 16Jose Carmona joins ADC Therapeutics as CFO
Dec 19ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M
Nov 08ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval
Sep 16ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11
Sep 09ADC Therapeutics Non-GAAP EPS of -$0.73, revenue of $17.29M misses by $13.93M
Aug 09Analysts Just Made A Meaningful Upgrade To Their ADC Therapeutics SA (NYSE:ADCT) Forecasts
Jul 21Sobi to pay ADC Therapeutics $55M upfront to license Zynlonta in Europe, other regions
Jul 08ADC Therapeutics begins dosing in study of Zynlonta combo for blood cancer subtype
Jun 29Is ADC Therapeutics (NYSE:ADCT) A Risky Investment?
Jun 22ADC Therapeutics SA (NYSE:ADCT) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 06Growth Investors: Industry Analysts Just Upgraded Their ADC Therapeutics SA (NYSE:ADCT) Revenue Forecasts By 21%
Mar 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$4m | US$721k | -US$240m |
| Sep 30 2023 | n/a | n/a | -US$179m |
| Jun 30 2023 | n/a | n/a | -US$181m |
| Mar 31 2023 | n/a | n/a | -US$199m |
| Dec 31 2022 | US$11m | US$475k | -US$157m |
Compensation vs Market: Ameet's total compensation ($USD3.78M) is above average for companies of similar size in the US market ($USD2.37M).
Compensation vs Earnings: Ameet's compensation has been consistent with company performance over the past year.
CEO
Ameet Mallik (50 yo)
1.9yrs
Tenure
US$3,779,425
Compensation
Dr. Ameet Mallik M.B.A., M.S, is Director at ADC Therapeutics SA from June 30, 2022. He has been a Director of Atara Biotherapeutics, Inc. since August 2021. Dr. Mallik serves as Chief Executive Officer at...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.9yrs | US$3.78m | 0.84% $ 3.1m | |
| Chief Financial Officer | 1.3yrs | US$1.26m | 0.17% $ 638.2k | |
| Chief Medical Officer | 1.3yrs | US$4.40m | 0.28% $ 1.0m | |
| Corporate Controller & Chief Accounting Officer | no data | no data | no data | |
| Chief Technical Operations Officer | 2.3yrs | no data | 0% $ 0 | |
| Chief Scientific Officer | 2.3yrs | no data | 0% $ 0 | |
| Investor Relations Officer | no data | no data | no data | |
| Chief Legal Officer | 1.4yrs | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Senior VP & Chief People Officer | 3.7yrs | no data | 0% $ 0 | |
| Chief Commercial Officer | 1.4yrs | no data | no data |
1.7yrs
Average Tenure
55.5yo
Average Age
Experienced Management: ADCT's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$3.78m | 0.84% $ 3.1m | |
| Board Observer | less than a year | US$4.33m | 0% $ 0 | |
| Vice-Chairman & Lead Independent Director | 4.8yrs | US$212.61k | 0.15% $ 549.8k | |
| Chairman of the Board | 4yrs | US$526.73k | 1.86% $ 6.8m | |
| Independent Non-Executive Director | 1.8yrs | US$206.58k | 0.048% $ 174.9k | |
| Independent Non-Executive Director | 5.8yrs | no data | no data | |
| Independent Non-Executive Director | 4yrs | US$140.60k | 0.071% $ 259.1k | |
| Independent Director | less than a year | US$127.67k | no data | |
| Independent Non-Executive Director | 2.8yrs | US$99.50k | 0.087% $ 318.4k | |
| Non-Independent Director | 7.5yrs | US$194.30k | 0.74% $ 2.7m |
3.4yrs
Average Tenure
56.5yo
Average Age
Experienced Board: ADCT's board of directors are considered experienced (3.4 years average tenure).